Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Consonance-Hfw Acq Corp (SRZN)

Consonance-Hfw Acq Corp (SRZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 32,668
  • Shares Outstanding, K 3,206
  • Annual Sales, $ 0 K
  • Annual Income, $ -43,040 K
  • EBIT $ -39 M
  • EBITDA $ -38 M
  • 60-Month Beta 0.91
  • Price/Sales 2.68
  • Price/Cash Flow N/A
  • Price/Book 5.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.97
  • Number of Estimates 1
  • High Estimate -1.97
  • Low Estimate -1.97
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.20%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.86 +14.72%
on 10/23/24
14.18 -28.28%
on 11/01/24
-1.00 (-8.95%)
since 10/08/24
3-Month
6.00 +69.50%
on 08/13/24
14.18 -28.28%
on 11/01/24
+3.07 (+43.24%)
since 08/08/24
52-Week
4.50 +126.00%
on 11/09/23
16.19 -37.18%
on 03/28/24
+3.87 (+61.47%)
since 11/08/23

Most Recent Stories

More News
Surrozen to Present at Upcoming Healthcare Investor Conferences

SRZN : 10.17 (-0.20%)
Surrozen Provides Third Quarter 2024 Financial Results and Business Update

SRZN : 10.17 (-0.20%)
Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

SRZN : 10.17 (-0.20%)
Surrozen Reports Second Quarter 2022 Financial Results

Phase 1 clinical trials of SZN-1326 and SZN-043 initiated and ongoingPreclinical proof-of-concept data for multiple programs presented and published in Q2...

SRZN : 10.17 (-0.20%)
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

SZN-043 is a novel hepatocyte-specific R-spondin mimetic bispecific fusion protein targeting ASGR1First part of two-part Phase 1 trial starts in healthy...

SRZN : 10.17 (-0.20%)
Surrozen Reports First Quarter 2022 Financial Results

On Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 and SZN-043 in the Third Quarter of 2022...

SRZN : 10.17 (-0.20%)
Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Preclinical data suggest that SZN-413 can simultaneously address retinal non-perfusion and leakage in blood vessels in retinal vascular diseases...

SRZN : 10.17 (-0.20%)
Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results

On Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 and SZN-043 in the Third Quarter of 2022...

SRZN : 10.17 (-0.20%)
Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Surrozen to provide a business update including discussion of pipeline advancements...

SRZN : 10.17 (-0.20%)
Surrozen Reports Third Quarter 2021 Financial Results

Product Candidates SZN-1326 and SZN-043 Advance Toward Initiation of Clinical Studies in 2022 Expanding and Advancing Discovery Stage Pipeline in Multiple...

SRZN : 10.17 (-0.20%)

Business Summary

Surrozen Inc. is a company pioneering targeted therapeutics which selectively activates the Wnt pathway for tissue repair and regeneration. Surrozen Inc., formerly known as Consonance-HFW Acquisition Corp., is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 11.59
2nd Resistance Point 11.02
1st Resistance Point 10.60
Last Price 10.17
1st Support Level 9.62
2nd Support Level 9.05
3rd Support Level 8.64

See More

52-Week High 16.19
Fibonacci 61.8% 11.72
Fibonacci 50% 10.35
Last Price 10.17
Fibonacci 38.2% 8.97
52-Week Low 4.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar